| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
As a chemical linker, TCO-PEG4-NHS ester does not have a specific biological target. It is used for the modification of biomolecules through NHS ester-mediated conjugation to primary amines. The PEG4 spacer improves water solubility, and the TCO group enables click chemistry reactions with tetrazines. The compound is used in PROTAC and ADC synthesis.
|
|---|---|
| ln Vitro |
Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC targets and selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system. An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
In vitro activity is not assessed for this compound as it is a chemical linker rather than a bioactive molecule. Its chemical reactivity and utility in bioconjugation, PROTAC synthesis, and ADC synthesis are the primary focus. |
| ln Vivo |
In vivo activity is not applicable for TCO-PEG4-NHS ester as it is not a pharmacologically active compound. The compound is used in research settings as a chemical linker for bioconjugation and drug delivery applications. It is not intended for therapeutic use.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not typically performed for TCO-PEG4-NHS ester, as it is a chemical linker rather than a bioactive compound. Its reactivity and conjugation efficiency are characterized by standard analytical techniques.
|
| Cell Assay |
In vitro cell-based assays are not applicable for TCO-PEG4-NHS ester as it is not a pharmacologically active compound. The compound is used in chemical synthesis and bioconjugation and is not evaluated for its effects on cell viability or other cellular functions.
|
| Animal Protocol |
In vivo animal studies are not performed for TCO-PEG4-NHS ester as it is not a pharmacologically active compound. The compound is used as a chemical linker and is not intended for therapeutic use. Any animal studies involving this compound would be limited to evaluating the pharmacokinetics of TCO-PEG4-conjugated molecules.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of TCO-PEG4-NHS ester are not characterized as the compound is not a drug candidate. The compound is water-soluble and can be easily conjugated to biomolecules such as proteins, peptides, and antibodies for imaging, targeting, and drug delivery applications. It is stored at appropriate temperatures for research use.
|
| Toxicity/Toxicokinetics |
Toxicity data for TCO-PEG4-NHS ester are limited to standard safety data sheets for handling and occupational exposure. The compound is for research use only and is not intended for diagnostic or therapeutic use. Appropriate safety precautions should be taken during handling.
|
| References | |
| Additional Infomation |
TCO-PEG4-NHS ester is a PEG-based PROTAC linker and a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). It is a water-soluble compound that can be easily conjugated to biomolecules such as proteins, peptides, and antibodies for imaging, targeting, and drug delivery applications. The PEG4 spacer improves water solubility compared to the non-PEGylated analog. TCO-PEG4-NHS ester is intended for laboratory research use only.
|
| Molecular Formula |
C24H38N2O10
|
|---|---|
| Molecular Weight |
514.56592798233
|
| Exact Mass |
514.252
|
| CAS # |
1613439-69-2
|
| Related CAS # |
(E)-TCO-PEG4-NHS ester;1621096-79-4;(S,E)-TCO2-PEG4-NHS ester
|
| PubChem CID |
118338101
|
| Appearance |
Colorless to light yellow ointment
|
| Density |
1.2±0.1 g/cm3
|
| Index of Refraction |
1.525
|
| LogP |
-0.09
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
36
|
| Complexity |
699
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(NCCOCCOCCOCCOCCC(=O)ON1C(CCC1=O)=O)=O)C1CCC=CCCC1
|
| InChi Key |
ZKPMRASGLDBKPF-UPHRSURJSA-N
|
| InChi Code |
InChI=1S/C24H38N2O10/c27-21-8-9-22(28)26(21)36-23(29)10-12-31-14-16-33-18-19-34-17-15-32-13-11-25-24(30)35-20-6-4-2-1-3-5-7-20/h1-2,20H,3-19H2,(H,25,30)/b2-1-
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-[[(4Z)-cyclooct-4-en-1-yl]oxycarbonylamino]ethoxy]ethoxy]ethoxy]ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~97.17 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9434 mL | 9.7169 mL | 19.4337 mL | |
| 5 mM | 0.3887 mL | 1.9434 mL | 3.8867 mL | |
| 10 mM | 0.1943 mL | 0.9717 mL | 1.9434 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
